Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

OncoImmunology

Volumn 4, Issue 4, 2015, Pages

  Buqué, Aitziber ^a,b,c   Bloy, Norma ^a,b,c,d   Aranda, Fernando ^e   Castoldi, Francesca ^a,b,c,d,f   Eggermont, Alexander ^a   Cremer, Isabelle ^b,c,g   Fridman, Wolf Hervé ^b,g,h   Fucikova, Jitka ^f,h   Galon, Jérôme ^b,c,g   Marabelle, Aurélien ^a,i   Spisek, Radek ^c,f   Tartour, Eric ^g,j,k   Zitvogel, Laurence ^a,i   Kroemer, Guido ^b,c,g,k,l   Galluzzi, Lorenzo ^a,b,c,g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f Sotio   (Czech Republic)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ University Paris XI   (France)

^j PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l Metabolomics and Cell Biology Platforms   (France)

more..

Author keywords

Ipilimumab; MEDI4736; MPDL3280A; Nivolumab; Pembrolizumab; Urelumab

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; B RAF KINASE; CP 870893; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACETUZUMAB; DOCETAXEL; DURVALUMAB; FRESOLIMUMAB; HYPOXIA INDUCIBLE FACTOR 1; IPILIMUMAB; LIRILUMAB; LUCATUMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PAZOPANIB; PEMBROLIZUMAB; PIDILIZUMAB; STAT3 PROTEIN; SUNITINIB; TICILIMUMAB; TOLL LIKE RECEPTOR; URELUMAB; VARLILUMAB;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL CYCLE CHECKPOINT; DRUG APPROVAL; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG TUMOR; MERKEL CELL TUMOR; METASTATIC MELANOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL;

EID: 84953445855     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1008814     Document Type: Article

References (309)

1. Colombel JF, SandbornWJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-95; PMID:20393175; http://dx. doi. org/10. 1056/NEJMoa0904492
2. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343:1594-602; PMID:11096166; http:// dx. doi. org/10. 1056/NEJM200011303432202
3. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997-1008; PMID:23460531; http://dx. doi. org/10. 1158/1078-0432. CCR-12-2214
4. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106; PMID:17251916; http://dx. doi. org/10. 1038/ nrc2051
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx. doi. org/ 10. 1038/nrc3239
6. Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints: a therapeutic target in triple negative breast cancer. Oncoimmunology 2014; 3: e28325; PMID:24843833; http://dx. doi. org/ 10. 4161/onci. 28325
7. Nowak AK. Immunological checkpoint inhibitors enter adolescence. Lancet Oncol 2013; 14:1035-7; PMID:24035406; http://dx. doi. org/10. 1016/S1470-2045(13)70401-7
8. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2013; 2:e24720; PMID:24073365; http://dx. doi. org/ 10. 4161/onci. 24720
9. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx. doi. org/10. 4161/ onci. 22009
10. Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 2014; 30C:24-31; PMID:24950501; http://dx. doi. org/10. 1016/j. coi. 2014. 05. 009
11. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7:411-23; PMID:15894262; http://dx. doi. org/10. 1016/j. ccr. 2005. 04. 014
12. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci U S A 2011; 108:10662-7; PMID:21670304; http://dx. doi. org/10. 1073/ pnas. 1100994108
13. Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2014; 33:4623-31; PMID:24141774; http://dx. doi. org/10. 1038/ onc. 2013. 432
14. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010; 11:21-7; PMID:20016506; http://dx. doi. org/10. 1038/ni. 1817
15. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-48; PMID:17063185; http:// dx. doi. org/10. 1038/nri1961
16. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx. doi. org/10. 1038/ni1102-991
17. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11:852-63; PMID:22116087; http://dx. doi. org/10. 1038/nri3108
18. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4:336-47; PMID:15122199; http:// dx. doi. org/10. 1038/nri1349
19. Waitz R, Fasso M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 2012; 1:544-6; PMID:22754781; http://dx. doi. org/10. 4161/onci. 19442
20. Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. Oncoimmunology 2013; 2:e23991; PMID:23734334; http:// dx. doi. org/10. 4161/onci. 23991
21. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx. doi. org/ 10. 4161/onci. 21335
22. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009; 10:1185-92; PMID:19783989; http://dx. doi. org/10. 1038/ni. 1790
23. Lipson EJ. Re-orienting the immune system: durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology 2013; 2:e23661; PMID:23734322; http://dx. doi. org/ 10. 4161/onci. 23661
24. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9:568-80; PMID:19629084; http://dx. doi. org/10. 1038/nri2604
25. Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev 2008; 224:85-97; PMID:18759922; http://dx. doi. org/ 10. 1111/j. 1600-065X. 2008. 00658. x
26. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008; 224:70-84; PMID:18759921; http://dx. doi. org/10. 1111/ j. 1600-065X. 2008. 00660. x
27. Schalper KA. PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer. Oncoimmunology 2014; 3:e29288; PMID:25083339; http://dx. doi. org/ 10. 4161/onci. 29288
28. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562-7; PMID:12704383; http://dx. doi. org/10. 1038/nm863
29. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8:467-77; PMID:18500231; http://dx. doi. org/ 10. 1038/nri2326
30. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999; 77:1-10; PMID:10101680; http://dx. doi. org/10. 1046/j. 1440-1711. 1999. 00795. x
31. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203:883-95; PMID:16606670; http://dx. doi. org/ 10. 1084/jem. 20051776
32. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94:107-16; PMID:24217091; http://dx. doi. org/10. 1038/labinvest. 2013. 130
33. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2014; 112:95-102; PMID:25349974; http://dx. doi. org/10. 1038/ bjc. 2014. 555
34. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014; 25:2178-84; PMID:25193987; http://dx. doi. org/10. 1093/annonc/ mdu445
35. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2:361-70; PMID:24764583; http://dx. doi. org/ 10. 1158/2326-6066. CIR-13-0127
36. Adler AJ, Vella AT. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology 2013; 2: e22837; PMID:23482891; http://dx. doi. org/ 10. 4161/onci. 22837
37. Withers DR, Gaspal FM, Bekiaris V, McConnell FM, Kim M, Anderson G, Lane PJ. OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev 2011; 244:134-48; PMID:22017436; http://dx. doi. org/10. 1111/j. 1600-065X. 2011. 01057. x
38. Croft M. The role of TNF superfamily members in Tcell function and diseases. Nat Rev Immunol 2009; 9:271-85; PMID:19319144; http://dx. doi. org/ 10. 1038/nri2526
39. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004; 4:420-31; PMID:15173831; http://dx. doi. org/10. 1038/nri1371
40. Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012; 1:458-66; PMID:22754764; http://dx. doi. org/10. 4161/onci. 19855
41. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682-5; PMID:9176498; http://dx. doi. org/ 10. 1038/nm0697-682
42. Houot R, Kohrt H, Levy R. Boosting antibodydependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 2012; 1:957-8; PMID:23162770; http://dx. doi. org/10. 4161/onci. 19974
43. Ye Q, Song DG, Powell DJ Jr. Finding a needle in a haystack: activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients. Oncoimmunology 2013; 2: e27184; PMID:24501691; http://dx. doi. org/ 10. 4161/onci. 27184
44. Shevach EM, Stephens GL. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol 2006; 6:613-8; PMID:16868552; http://dx. doi. org/10. 1038/nri1867
45. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3:135-42; PMID:11812990; http://dx. doi. org/10. 1038/ni759
46. Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2013; 2:e25581; PMID:24319633; http://dx. doi. org/ 10. 4161/onci. 25581
47. Schnurr M, Duewell P. Breaking tumor-induced immunosuppression with 5'-triphosphate siRNA silencing TGFbeta and activating RIG-I. Oncoimmunology 2013; 2:e24170; PMID:23762798; http://dx. doi. org/10. 4161/onci. 24170
48. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013; 13:788-99; PMID:24132110; http:// dx. doi. org/10. 1038/nrc3603
49. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-betaproducing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006; 177:896-904; PMID:16818744; http://dx. doi. org/10. 4049/jimmunol. 177. 2. 896
50. Hussain SF, Paterson Y. CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J Immunother 2004; 27:339-46; PMID:15314542; http://dx. doi. org/ 10. 1097/00002371-200409000-00002
51. Chen ZM, O'Shaughnessy MJ, Gramaglia I, Panoskaltsis-Mortari A, Murphy WJ, Narula S, Roncarolo MG, Blazar BR. IL-10 and TGF-beta induce alloreactive CD4+CD25-T cells to acquire regulatory cell function. Blood 2003; 101:5076-83; PMID:12609834; http://dx. doi. org/10. 1182/blood-2002-09-2798
52. Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014; 3: e967147; http://dx. doi. org/10. 4161/ 21624011. 2014. 967147
53. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx. doi. org/10. 4161/ onci. 27297
54. Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http:// dx. doi. org/10. 4161/onci. 22789
55. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx. doi. org/10. 1056/NEJMoa1003466
56. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy. Nat Rev Drug Discov 2010; 9:584; http://dx. doi. org/10. 1038/ nrd3245. PMID 20671754
57. Erdmann MK. Immunity unleashed in melanoma. Lancet Oncol 2010; 11:108-9; PMID:20152761; http://dx. doi. org/10. 1016/S1470-2045(09)70400-0
58. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx. doi. org/10. 1016/S1470-2045(09)70334-1
59. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011; 10:411-2; PMID:21629286; http://dx. doi. org/ 10. 1038/nrd3463
60. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http:// dx. doi. org/10. 1038/nature13954
61. PD-1 Inhibitor Approved for Melanoma. Cancer Discov 2014; 4:1249; PMID:25367933; http://dx. doi. org/10. 1158/2159-8290. CD-NB2014-144
62. Poole RM. Pembrolizumab: first global approval. Drugs 2014; 74:1973-81; PMID:25331768; http:// dx. doi. org/10. 1007/s40265-014-0314-5
63. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; http://dx. doi. org/10. 1016/ S0140-6736(14)60958-2
64. Bagcchi S. Pembrolizumab for treatment of refractory melanoma. Lancet Oncol 2014; 15:e419; PMID:25328942; http://dx. doi. org/10. 1016/S1470-2045(14)70348-1
65. Deeks ED. Nivolumab: a review of its use in patients with malignant melanoma. Drugs 2014; 74:1233-9; PMID:25022950; http://dx. doi. org/10. 1007/s40265-014-0234-4
66. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2014; 372:320-30; PMID:25399552; http://dx. doi. org/10. 1056/NEJMoa1412082
67. Dai M, Yip YY, Hellstrom I, Hellstrom KE. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res 2014; PMID:25142145; http://dx. doi. org/ 10. 1158/1078-0432. CCR-14-1339
68. Wei H, Zhao L, Hellstrom I, Hellstrom KE, Guo Y. Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy. Oncoimmunology 2014; 3:e28248; PMID:25050196; http://dx. doi. org/10. 4161/ onci. 28248
69. Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx. doi. org/10. 4161/ onci. 29030
70. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx. doi. org/10. 4161/ onci. 28694
71. Antonia SJ, Gettinger SN, Chow LQM, Juergens RA, Borghaei H, Shen Y, Harbison C, Chen AC, Ready N, Rizvi NA. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. ASCO Meeting Abstracts 2014; 32:8023
72. Ariyan CE, Lefkowitz RA, Panageas K, Callahan MK, Misholy O, Bello D, Fisher C, Kotin A, Siegelbaum R, Coit DG, et al. Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in patients with in-transit melanoma. ASCO Meeting Abstracts 2014; 32:9078
73. Bauman JE, Gooding WE, Clump DA, Kim S, Karlovits BJ, Heron DE, Duvvuri U, Ohr J, Holeva K, Ferris RL. Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). ASCO Meeting Abstracts 2014; 32:TPS6104
74. Beer TM, Logothetis C, GerritsenWR, Kwon ED, Scher HI, Bossi A, van den Eertwegh AJM, Drake CG, McHenry B, Liu D, et al. Characterization of immunerelated adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC. ASCOMeeting Abstracts 2014; 32:52
75. Bjoern J, Donia M, Andersen R, Reker Hadrup S, Lyngaa R, Svane IM. Effects of ipilimumab on expanded tumor-infiltrating lymphocytes in patients with stage IV malignant melanoma. ASCO Meeting Abstracts 2014; 32:3020
76. Callahan MK, Bendell JC, Chan E, Morse M, Pillai RN, Bono P, Jaeger D, Evans TRJ, Chau I, Calvo E, et al. Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. ASCO Meeting Abstracts 2014; 32: TPS3114
77. Chasset F, Pages C, Biard L, Roux J, Sidina I, Madelaine I, Basset-Seguin N, Viguier M, Madjlessi N, Schneider P, et al. Single-center experience in French Temporary Authorization for Use (TAU) metastatic melanoma program with ipilimumab. ASCO Meeting Abstracts 2014; 32:e20034
78. Deo MA. Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients. ASCO Meeting Abstracts 2014; 32:3060
79. Diab A, McArthur HL, Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Blum B, Yuan J, Patil S, et al. A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). ASCO Meeting Abstracts 2014; 32:1098
80. Drake CG, Kwon ED, Fizazi K, Bossi A, van den Eertwegh AJ, Logothetis C, Scher HI, Beer TM, McHenry B, Liu D, et al. Results of subset analyses on overall survival (OS) from study CA184-043: ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts 2014; 32:2
81. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Meeting Abstracts 2014; 32:LBA9008
82. Gibney GT, Hamid O, Gangadhar TC, Lutzky J, Olszanski AJ, Gajewski T, Chmielowski B, Boasberg PD, Zhao Y, Newton RC, et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. ASCO Meeting Abstracts 2014; 32:3010
83. Hamid O, Robert C, Ribas A, Wolchok JD, Hodi FS, Kefford R, Joshua AM, Hwu W-J, Gangadhar TC, Patnaik A, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). ASCO Meeting Abstracts 2014; 32:3000
84. Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Razak ARA, Pal SK, Voss MH, Sharma P, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2014; 32:4504
85. Hendler RC, Wu S. Risk of severe diarrhea associated with ipilimumab in cancer patients. ASCO Meeting Abstracts 2014; 32:9634
86. Hodi FS, Sznol M, Kluger HM, McDermott DF, Carvajal RD, Lawrence DP, Topalian SL, Atkins MB, Powderly JD, Sharfman WH, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. ASCO Meeting Abstracts 2014; 32:9002
87. Hu JL, Sharma P, Yu J, Black KL, Rudnick JD. Ipilimumab for recurrent glioblastoma: a single-institution case series. ASCO Meeting Abstracts 2014; 32:e13010
88. Jamal R, Belanger K, Friedmann JE, Ayoub J-PM, Cocolakis E, Kazemi S, Dionne J, Lambert C, Le HB, Van Kempen L, et al. A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). ASCO Meeting Abstracts 2014; 32:9066
89. Johnson DB, Peng C, Abramson RG, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Ipilimumab in acral melanoma: a retrospective review. ASCO Meeting Abstracts 2014; 32:9056
90. Kaufman HL, Mehnert JM, Cuillerot J-M, von Heydebreck A, Ott PA, Hodi FS. Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: assessment of safety, clinical, and biologic activity in a phase 2a study. ASCO Meeting Abstracts 2014; 32:TPS9107
91. Kennedy E, Rossi GR, Vahanian NN, Link CJ. Phase 1/2 trial of the indoleamine 2, 3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma. ASCO Meeting Abstracts 2014; 32:TPS9117
92. Kudchadkar RR, Gibney GT, Dorman D, Merek S, Ramadan H, Chen A, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma. ASCO Meeting Abstracts 2014; 32:9098
93. Lee-Ying RM, Feng X, Smylie M, Monzon JG, Cheng T. Efficacy of two ipilimumab (IPI) doses (10-vs. 3-mg/kg) in Alberta, Canada, tertiary cancer centers. ASCO Meeting Abstracts 2014; 32:9090
94. Lheureux S, Butler MO, Fleming GF, Hirte HW, Cristea MC, Ghatage P, Martin LP, Mackay H, Dhani NC, Wilson M, et al. A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: a study of the princess margaret and chicago N01 consortia. ASCO Meeting Abstracts 2014; 32:TPS5631
95. Momtaz P, Gaskell AA, Merghoub T, Viale A, Chapman PB. Correlation of tumor-derived circulating cell free DNA (cfDNA) measured by digital PCR (DigPCR) with tumor burden measured radiographically in patients (pts) with BRAFV600Emutated melanoma (mel) treated with RAF inhibitor (RAFi) and/ or ipilimumab (Ipi). ASCO Meeting Abstracts 2014; 32:9085
96. Moser J, Pulido J, Dronca RS, Markovic S, Mansfield AS. The Mayo Clinic experience with the use of kinase inhibitors (KIs), ipilimumab, and bevacizumab in the treatment of metastatic ocular melanoma. ASCO Meeting Abstracts 2014; 32:e20011
97. Neyns B, Wilgenhof S, Corthals J, Heirman C, Thielemans K. Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma. ASCO Meeting Abstracts 2014; 32:3014
98. Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, et al. T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). ASCO Meeting Abstracts 2014; 32:3021
99. Page DB, Yuan J, Ginsberg A, Dong Z, Wong P, Emerson R, Sung JS, Comstock C, Solomon SB, Sacchini V, et al. Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). ASCO Meeting Abstracts 2014; 32:64
100. Patel RK, Ko AH, Onners B, Uram JN, Parkinson R, Sugar E, Lutz E, Zheng L, Laheru DA, Jaffee EM, etal. A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer. ASCO Meeting Abstracts 2014; 32:TPS4160
101. Pavlick AC, Chandra S, Stein C, Madden KM, Kannan R, Escano C, Muren C, Yepes E, Sabado RL, Bhardwaj N, et al. Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma. ASCO Meeting Abstracts 2014; 32:e20025
102. Piulats Rodriguez JM, Ochoa de Olza M, Codes M, Lopez-Martin JA, Berrocal A, Garcia M, Gurpide A, Homet B, Martin-Algarra S. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial. ASCO Meeting Abstracts 2014; 32:9033
103. Puzanov I, Callahan MK, Linette GP, Patel SP, Luke JJ, Sosman JA, Wolchok JD, Hamid O, Minor DR, Orford KW, et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). ASCO Meeting Abstracts 2014; 32:2511
104. Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chastain M, Gorski K, Anderson A, Vanderwalde AM, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO Meeting Abstracts 2014; 32:9029
105. Riker AI, Rossi GR, Vahanian NN, Link CJ. NLG-0304: a phase 2B study of ipilimumab with or without dorgenmeltucel-L (HyperAcute-Melanoma) immunotherapy for patients with stage IV melanoma. ASCO Meeting Abstracts 2014; 32:TPS9115
106. Sampson JH, Vlahovic G, Desjardins A, Friedman HS, Baehring JM, Hafler D, Rollin L, Coric V, Perez SN, Reardon DA. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). ASCO Meeting Abstracts 2014; 32:TPS2101
107. Schaff LR, Lassman AB, Goldlust SA, Cloughesy TF, Singer S, Schwartz GK, Iwamoto FM. Ipilimumab for recurrent glioblastoma (GBM). ASCO Meeting Abstracts 2014; 32:e13026
108. Schindler K, Harmankaya K, Kuk D, Mangana J, Michielin O, Hoeller C, Dummer R, Pehamberger H, Wolchok JD, Postow MA. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. ASCO Meeting Abstracts 2014; 32:9096
109. Schmerling R, Herchenhorn D, Rinck JA, Camargo VPD, Camargo J, Serrano SV, Azevedo SJ, Barrios CH, Segalla JGM, Bertoni VD, et al. Ipilimumab for stage unresectable III/IV melanoma: Brazilian experience in an expanded access program. ASCO Meeting Abstracts 2014; 32:e20045
110. Shoukat S, Marcus DM, Rizzo M, Lawson DH, Khosa F, Liu Y, Patel KR, Khan MK. Outcome with stereotactic radiosurgery (SRS) and ipilimumab (Ipi) for malignant melanoma brain metastases (mets). ASCO Meeting Abstracts 2014; 32:9076
111. Snyder Charen A, Makarov V, Merghoub T, Walsh L, Yuan J, Miller M, Kannan K, Postow MA, Elipenahli C, Liu C, et al. The neoantigen landscape underlying clinical response to ipilimumab. ASCO Meeting Abstracts 2014; 32:3003
112. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). ASCO Meeting Abstracts 2014; 32:LBA9003
113. Tarhini AA, LaFramboise WA, Petrosko P, Deamont CG, Kirkwood JM. Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity. ASCO Meeting Abstracts 2014; 32:9024
114. Tavares MC, De Barros E, Silva MJ, Rinck JA, Urvanegia ACM, Macedo MP, Pinto C, Bezerra T, Dal Molin GZ, Santos FN, et al. Number of sites of metastasis (NSM) and progression-free survival (PFS) in patients (PTS) with melanoma treated with ipilimumab (IPI). ASCO Meeting Abstracts 2014; 32: e20048
115. Weber JS, Kudchadkar RR, Gibney GT, Yu B, Cheng P, Martinez AJ, Kroeger J, Gallenstein D, Richards A, Welsh E, et al. Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI). ASCO Meeting Abstracts 2014; 32:3009
116. Zimmer L, Eigentler TK, Vaubel J-M, Mohr P, Jradi Z, Kiecker F, Utikal J, Berking C, Kämpgen E, Hauschild A, et al. Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups. ASCO Meeting Abstracts 2014; 32:9031
117. Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, Sophie T, Thomas J, Jean-Jacques G, Marie-Aleth R, et al. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Acta Derm Venereol 2014; 94:45-9; PMID:23824275; http://dx. doi. org/10. 2340/ 00015555-1654
118. Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabr L, Danielli R, de Rosa F, Maur M, et al. Clinical experience with ipilimumab 10-mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res 2013; 32:82; PMID:24423086; http://dx. doi. org/10. 1186/1756-9966-32-82
119. Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 2014; 32:144-9; PMID:24484235; http://dx. doi. org/10. 3109/07357907. 2014. 885984
120. Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 2014; 63:407-18; PMID:24514956; http://dx. doi. org/10. 1007/s00262-014-1524-0
121. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, etal. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63:449-58; PMID:24609989
122. Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 2014; 33:30; PMID:24708900; http://dx. doi. org/10. 1186/1756-9966-33-30
123. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15:700-12; PMID:24831977; http://dx. doi. org/10. 1016/S1470-2045(14)70189-5
124. Lebbe C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014; 25:2277-84; PMID:25210016; http://dx. doi. org/10. 1093/annonc/mdu441
125. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014; 312:1744-53; PMID:25369488; http://dx. doi. org/10. 1001/ jama. 2014. 13943
126. Garcia-Manero G, Martinelli G, Zeidner JF, Avigan D, Anderson KC, Ribrag V, Moskowitz C, Zinzani PL, Wu D, Emancipator K, et al. A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies. ASCO Meeting Abstracts 2014; 32:TPS3116
127. Garon EB, Leighl NB, Rizvi NA, Blumenschein GR, Balmanoukian AS, Eder JP, Goldman JW, Hui R, Soria J-C, Gangadhar TC, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32:8020
128. Herbst RS, Gurpide A, Surmont V, Kim D-W, Waqar SN, Herder J, Lee DH, Carcereny E, Reguart N, Wallmark JM, et al. A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer. ASCO Meeting Abstracts 2014; 32:TPS8124
129. Hodi FS, Ribas A, Daud A, Hamid O, Robert C, Kefford R, Hwu W-J, Gangadhar TC, Joshua AM, Hersey P, et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstracts 2014; 32:3006
130. Joseph RW, Elassaiss-Schaap J, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Hwu W-J, et al. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstracts 2014; 32:3015
131. Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, Joshua AM, Hodi FS, Gangadhar TC, Hersey P, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Meeting Abstracts 2014; 32:3005
132. Le DT, Azad NS, Laheru D, Browner IS, Wang H, Uram JN, Kemberling H, Zheng L, Iannone R, Friedman E, et al. Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. ASCO Meeting Abstracts 2014; 32:TPS3128
133. McDermott DF, Infante JR, Voss MH, Motzer RJ, Haanen JBAG, Chowdhury S, Perini RF, Iannone R, Hodge R, Figueroa D, et al. A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma. ASCO Meeting Abstracts 2014; 32:TPS4604
134. Nanda R, Plimack ER, Dees EC, Gupta S, Berger R, Elfiky A, Pusztai L, Buisseret L, Geva R, Pai SI, et al. A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors. ASCO Meeting Abstracts 2014; 32:TPS3119
135. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, Hwu W-J, Gangadhar TC, Patnaik A, Joshua AM, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO Meeting Abstracts 2014; 32:LBA9000
136. Rizvi NA, Garon EB, Patnaik A, Gandhi L, Leighl NB, Balmanoukian AS, Goldman JW, Eder JP, Johnson E, Blumenschein GR, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32:8007
137. Seiwert TY, Burtness B, Weiss J, Gluck I, Eder JP, Pai SI, Dolled-Filhart M, Emancipator K, Pathiraja K, Gause C, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. ASCO Meeting Abstracts 2014; 32:6011
138. Siegel DSD, Moreau P, Avigan D, Anderson KC, Reece DE, San Miguel J, Mateos M-V, Wu D, Emancipator K, Dolled-Filhart M, et al. A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO Meeting Abstracts 2014; 32:TPS3117
139. Moskowitz CH, Ribrag V, Michot JM, Martinelli G, Zinzani PL, Gutierrez M, De Maeyer G, Jacob AG, Giallella K, Anderson JW, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1b study. ASH Annual Meeting Abstracts 2014; Session 624:Abstract 290
140. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez EJ, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. San Antonio Breast Cancer Symposium Abstracts 2014:S1-09.
141. Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Knox JJ, Pal SK, Voss MH, Sharma P, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2014; 32:5010
142. Antonia SJ, Brahmer JR, Gettinger SN, Chow LQM, Juergens RA, Shepherd FA, Laurie SA, Gerber DE, Goldman JW, Shen Y, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32:8113
143. Brahmer JR, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Leming PD, Topalian SL, Hodi FS, Sznol M, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. ASCO Meeting Abstracts 2014; 32:8112
144. Carbone DP, Socinski MA, Chen AC, Bhagavatheeswaran P, Reck M, Paz-Ares L. A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32: TPS8128
145. Choueiri TK, Fishman MN, Escudier BJ, Kim JJ, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. ASCO Meeting Abstracts 2014; 32:5012
146. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Juergens RA, Borghaei H, Shen Y, Harbison C, Alaparthy S, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. ASCO Meeting Abstracts 2014; 32:8024
147. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. ASCO Meeting Abstracts 2014; 32:5511
148. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel T, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. ASCO Meeting Abstracts 2014; 32:5009
149. Porkka K, Mauro MJ, Lipton JH, Mahon F-X, Strauss LC, Geese WJ, Kroog GS, Mustjoki S. An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML). ASCO Meeting Abstracts 2014; 32: TPS7119
150. Rizvi NA, Chow LQM, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen AC, Gettinger SN. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. ASCO Meeting Abstracts 2014; 32:8022
151. Segal NH, Hodi FS, Sanborn RE, Gajewski T, Wolchok JD, Urba WJ, Fox BA, Topalian SL, Pardoll DM, Kollia G, et al. A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. ASCO Meeting Abstracts 2014; 32:TPS3115
152. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013; 31:4311-8; PMID:24145345; http://dx. doi. org/10. 1200/ JCO. 2013. 51. 4802
153. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http:// dx. doi. org/10. 1200/JCO. 2013. 53. 0105
154. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, et al. Preliminary results of a Phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. ASH Annual Meeting Abstracts 2014; Session 624: Abstract 291
155. Calabro L, Morra A, Fonsatti E, Cutaia O, Fazio C, Danielli R, Giannarelli D, Altomonte M, Di Giacomo AM, Maio M. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in secondline mesothelioma patients. ASCO Meeting Abstracts 2014; 32:7531
156. Callahan MK, Ott PA, Odunsi K, Bertolini SV, Pan LS, Venhaus RR, Karakunnel JJ, Hodi FS, Wolchok JD. A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. ASCO Meeting Abstracts 2014; 32:TPS3120
157. Duffy AG, Ulahannan SV, Fioravanti S, Walker M, Figg WD, Compton K, Venkatesan A, Abi-Jaoudeh N, Wood BJ, Greten TF. A pilot study of tremelimumab, a monoclonal antibody against CTLA-4, in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). ASCO Meeting Abstracts 2014; 32:e15133
158. Maio M, Scherpereel A, Di Pietro A, Vasey P, Tsao AS, Calabro L, Fu D, Robbins PB, Ibrahim RA, Kindler HL. Randomized, double-blind, placebo-controlled study of tremelimumab for second-and thirdline treatment of unresectable pleural or peritoneal mesothelioma. ASCO Meeting Abstracts 2014; 32: TPS7609
159. Pinder MC, Rizvi NA, Goldberg SB, Balmanoukian AS, Narwal R, Robbins PB, D'Angelo G, Blake-Haskins A, Karakunnel JJ, Antonia SJ. A phase 1b openlabel study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced nonsmall cell lung cancer. ASCO Meeting Abstracts 2014; 32:e19137
160. Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, et al. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res 2014; 20:3310-8; PMID:24721645; http://dx. doi. org/10. 1158/1078-0432. CCR-13-2906
161. Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH Jr, Bagala C, Aglietta M, Barone C, Sawyer MB, Moore MJ, et al. A phase I dose escalation trial of tremelimumab (CP-675, 206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol 2014; 25:1750-5; PMID:24907635; http://dx. doi. org/ 10. 1093/annonc/mdu205
162. Atkins MB, Kudchadkar RR, Sznol M, McDermott DF, Lotem M, Schachter J, Wolchok JD, Urba WJ, Kuzel T, Schuchter LM, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. ASCO Meeting Abstracts 2014; 32:9001
163. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15:69-77; PMID:24332512; http://dx. doi. org/ 10. 1016/S1470-2045(13)70551-5
164. Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, Robbins PB, Vasselli J, Ibrahim RA, Antonia SJ. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. ASCO Meeting Abstracts 2014; 32:8021
165. Fairman D, Narwal R, Liang M, Robbins PB, Schneider A, Chavez C, Lu H, Pak M, Blake-Haskins A, Vasselli J, et al. Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts 2014; 32:2602
166. Gordon MS, Lutzky J, Lawrence DP, Orford KW, Blake-Haskins A, Di Pietro A, Robbins PB, Dar MM, Ribas A. Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma. ASCO Meeting Abstracts 2014; 32:TPS9108
167. Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB, Shalabi AM, Vasselli J, Ibrahim RA, Khleif S, Segal NH. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts 2014; 32:3001
168. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, Vasselli J, Ibrahim RA, Lutzky J, Khleif S. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meeting Abstracts 2014; 32:3002
169. Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Zambrano CC, Bellmunt J, Burris HA, Melinda Teng S-L, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meeting Abstracts 2014; 32:5011
170. Rizvi NA, Chow LQM, Dirix LY, Gettinger SN, Gordon MS, Kabbinavar FF, Von Pawel J, Soria J-C, Chappey C, Mokatrin A, et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with nonsmall cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32:TPS8123
171. Emens LA, Braiteh FS, Cassier P, Delord JP, Eder JP, Shen X, Xiao Y, Wang Y, Hegde PS, Chen DS, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium Abstracts 2014:PD1-6.
172. Heery CR, O'Sullivan Coyne GH, Madan RA, Schlom J, von Heydebreck A, Cuillerot J-M, Sabzevari H, Gulley JL. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PDL1 monoclonal antibody, in advanced solid malignancies. ASCO Meeting Abstracts 2014; 32:3064
173. Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014; 99:e81-3; PMID:24658821; http://dx. doi. org/10. 3324/ haematol. 2013. 103085
174. Segal NH, Gopal AK, Bhatia S, Kohrt HE, Levy R, Pishvaian MJ, Houot R, Bartlett N, Nghiem P, Kronenberg SA, et al. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. ASCO Meeting Abstracts 2014; 32:3007
175. Chester C, Chang S, Kurland JF, Sagiv-Barfi I, Czerwinski D, Rajapaksa A, Waller E, Sadaram M, Richards L, Cohen LJ, et al. Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma. ASCO Meeting Abstracts 2014; 32:3017
176. Ansell SM, Northfelt DW, Flinn I, Burris HA, Dinner SN, Villalobos VM, Sikic BI, Taylor MH, Pilja L, Hawthorne TR, et al. Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. ASCO Meeting Abstracts 2014; 32:3024
177. Infante JR, Burris HA, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE, et al. Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors. ASCO Meeting Abstracts 2014; 32:3027
178. Chowdhury F, Johnson PW, Glennie MJ, Williams AP. Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial. Cancer Immunol Res 2014; 2:229-40; PMID:24778319; http://dx. doi. org/10. 1158/2326-6066. CIR-13-0070
179. de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, et al. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol 2014; 7:44; PMID:24919462; http://dx. doi. org/10. 1186/ 1756-8722-7-44
180. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013; 73:7189-98; PMID:24177180; http://dx. doi. org/10. 1158/0008-5472. CAN-12-4174
181. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 2014; 9:e90353; PMID:24618589; http://dx. doi. org/10. 1371/journal. pone. 0090353
182. Junker N, Donia M, Andersen R, Andersen MH, Svane IM. PD-L1 specific tumor infiltrating lymphocytes occur frequently in melanoma and HNSCC patients. ASCO Meeting Abstracts 2014; 32:11083
183. Flaherty K, Daud A, Weber JS, Sosman JA, Kim K, Gonzalez R, Hamid O, Infante JR, Cebon JS, Schuchter LM, et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). ASCO Meeting Abstracts 2014; 32:9010
184. Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabro L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 2014; 110:1721-6; PMID:24619072; http://dx. doi. org/10. 1038/bjc. 2014. 126
185. Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A, Romero P, Speiser DE, Triebel F, Leyvraz S, et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 2014; 12:97; PMID:24726012; http://dx. doi. org/10. 1186/1479-5876-12-97
186. Calles A, Liao X, Sholl LM, Butaney M, Rodig SJ, Freeman GJ, Lydon CA, Oxnard GR, Jackman DM, Janne PA. Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers. ASCO Meeting Abstracts 2014; 32:8032
187. Ansen S, Schultheis AM, Hellmich M, Zander T, Brockmann M, Stoelben E, Groen HJM, Timens W, Buettner R, Thomas RK, et al. PD-L1 expression and genotype in non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32:7517
188. Fay AP, Callea M, Gray KP, Ho TH, Song J, Carvo I, Lampron ME, Albiges L, Stanton ML, McDermott DF, et al. PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors. ASCO Meeting Abstracts 2014; 32:4526
189. Callea M, Genega EM, Gupta M, Cheng S, Fay AP, Song J, Carvo I, Bhatt RS, McDermott DF, Atkins MB, et al. PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. ASCO Meeting Abstracts 2014; 32:4585
190. Denkert C, Von Minckwitz G, Brase JC, Darb-Esfahani S, Gade S, Kronenwett R, Salat C, Loi S, Schem C, Sotiriou C, et al. Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: prediction of response to carboplatin-based chemotherapy. ASCO Meeting Abstracts 2014; 32:510
191. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http:// dx. doi. org/10. 1056/NEJMoa1103782
192. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx. doi. org/ 10. 1056/NEJMoa1302369
193. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx. doi. org/10. 1056/ NEJMc1302338
194. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2014; 372:311-9; PMID:25482239; http://dx. doi. org/10. 1056/ NEJMoa1411087
195. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81; PMID:25428507; http://dx. doi. org/10. 1038/nature13988
196. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99; PMID:25409260; http://dx. doi. org/ 10. 1056/NEJMoa1406498
197. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx. doi. org/10. 1038/ nature14011
198. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211:781-90; PMID:24778419; http://dx. doi. org/10. 1084/jem. 20131916
199. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 2014; 211:715-25; PMID:24687957; http://dx. doi. org/10. 1084/ jem. 20130590
200. Madireddi S, Eun SY, Lee SW, Nemcovicova I, Mehta AK, Zajonc DM, Nishi N, Niki T, Hirashima M, Croft M. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med 2014; 211:1433-48; PMID:24958847; http://dx. doi. org/ 10. 1084/jem. 20132687
201. Kong KF, Fu G, Zhang Y, Yokosuka T, Casas J, Canonigo-Balancio AJ, Becart S, Kim G, Yates JR 3rd, Kronenberg M, et al. Protein kinase C-eta controls CTLA-4-mediated regulatory T cell function. Nat Immunol 2014; 15:465-72; PMID:24705298; http:// dx. doi. org/10. 1038/ni. 2866
202. Herrmann A, Priceman SJ, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest 2014; 124:2977-87; PMID:24892807; http://dx. doi. org/10. 1172/ JCI73174
203. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PDL1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124:687-95; PMID:24382348; http://dx. doi. org/10. 1172/ JCI67313
204. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Desbois M, Chaput N, Klatzmann D, Jacquelot N, Vimond N, Chouaib S, et al. IL-2-dependent antitumor effects of ipilimumab: high soluble CD25 levels predict resistance to therapy. Cell Res 2015; 25:208-24; in press; PMID:25582080; http://dx. doi. org/ 10. 1038/cr. 2015. 3
205. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015:; 212(2):139-48; PMID:25601652; http://dx. doi. org/10. 1084/jem. 20140559
206. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25:876-83; PMID:17327609; http://dx. doi. org/10. 1200/ JCO. 2006. 08. 3311
207. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013; 25:230-7; PMID:23414607; http://dx. doi. org/ 10. 1016/j. coi. 2013. 01. 004
208. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009; 206:1103-16; PMID:19414558; http://dx. doi. org/10. 1084/ jem. 20082205
209. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, Bergqvist S, Baxi SM, Rohner A, Shen AC, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 2012; 61:1721-33; PMID:22406983; http://dx. doi. org/10. 1007/s00262-012-1237-1
210. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive Tcell therapy. PLoS One 2013; 8:e60031; PMID:23560068; http://dx. doi. org/10. 1371/journal. pone. 0060031
211. Shirwan H, Sharma RK, Srivastava AK, Yolcu ES. Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines. Oncoimmunology 2013; 2: e23440; PMID:23734306; http://dx. doi. org/ 10. 4161/onci. 23440
212. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med 2012; 10:236; PMID:23171508; http://dx. doi. org/10. 1186/1479-5876-10-236
213. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-22; PMID:23295794; http://dx. doi. org/10. 1200/JCO. 2012. 44. 6112
214. Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer 2013; 108:1998-2004; PMID:23652314; http:// dx. doi. org/10. 1038/bjc. 2013. 227
215. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2014; PMID:24917416
216. Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther 2010; 12:724-33; PMID:21154164
217. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3: e27878; PMID:24800173; http://dx. doi. org/ 10. 4161/onci. 27878
218. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx. doi. org/10. 4161/ onci. 23510
219. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx. doi. org/ 10. 1146/annurev-immunol-032712-100008
220. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx. doi. org/ 10. 1038/nrc3380
221. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798;' http://dx. doi. org/10. 1038/ nrd3626
222. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http:// dx. doi. org/10. 1016/j. immuni. 2013. 06. 014
223. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10:514-23; PMID:20535131; http://dx. doi. org/10. 1038/ nrc2870
224. Herbst RS, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004; 4:956-65; PMID:15573117; http://dx. doi. org/ 10. 1038/nrc1506
225. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx. doi. org/10. 4161/ onci. 25595
226. Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: radioimmunotherapy for oncological indications. Oncoimmunology 2014; 3:e954929; http://dx. doi. org/10. 4161/21624011. 2014. 954929
227. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012; 12:436-44; PMID:22555283; http:// dx. doi. org/10. 1038/nrc3247
228. Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer 2010; 10:205-12; PMID:20147902; http://dx. doi. org/10. 1038/nrc2795
229. Ellem SJ, Risbridger GP. Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 2007; 7:621-7; PMID:17611544; http://dx. doi. org/10. 1038/nrc2174
230. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 2013; 10:507-18; PMID:23881033; http://dx. doi. org/10. 1038/nrclinonc. 2013. 123
231. Mitsudomi T, Suda K, Yatabe Y. Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol 2013; 10:235-44; PMID:23438759; http://dx. doi. org/10. 1038/nrclinonc. 2013. 22
232. Weiss C, Rodel C. Surgical oncology. Alternatives to surgery after failure of instillation therapy. Nat Rev Clin Oncol 2010; 7:307-8; PMID:20517340; http:// dx. doi. org/10. 1038/nrclinonc. 2010. 69
233. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265
234. Weiner LM. Building better magic bullets-improving unconjugated monoclonal antibody therapy for cancer. Nat Rev Cancer 2007; 7:701-6; PMID:17721434; http://dx. doi. org/10. 1038/nrc2209
235. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100-years of progress. Nat Rev Cancer 2008; 8:473-80; PMID:18469827; http://dx. doi. org/ 10. 1038/nrc2394
236. Humphries C. Adoptive cell therapy: honing that killer instinct. Nature 2013; 504:S13-5; PMID:24352359; http://dx. doi. org/10. 1038/ 504S13a
237. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014; 32:189-225; PMID:24423116; http://dx. doi. org/10. 1146/ annurev-immunol-032713-120136
238. Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx. doi. org/ 10. 4161/onci. 24850
239. Papatriantafyllou M. Cytokines: true to their family name. Nat Rev Immunol 2013; 13:544-5; PMID:23827957; http://dx. doi. org/10. 1038/nri3496
240. Chen P, Balachandran S. Development of interferon gamma-based immunocytokines targeting renal cancer. Oncoimmunology 2013; 2:e24964; PMID:24073376; http://dx. doi. org/10. 4161/ onci. 24964
241. Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, et al. Trial watch: dendritic cell-based anticancer therapy. Oncoimmunology 2014; 3: e963424;10. 4161/21624011. 2014. 963424
242. Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucikova J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:24286020; http://dx. doi. org/ 10. 4161/onci. 25771
243. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2014; 3:e28185; PMID:24800178; http://dx. doi. org/10. 4161/onci. 28185
244. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; http://dx. doi. org/10. 4161/ onci. 23803
245. Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx. doi. org/10. 4161/ onci. 26621
246. Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautes-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: peptide-based anticancer vaccines. Oncoimmunology 2014; 3:e974411; http://dx. doi. org/10. 4161/2162402X. 2014. 974411
247. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108-20; PMID:18219306; http://dx. doi. org/10. 1038/ nrc2326
248. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx. doi. org/10. 1038/ nrc3258
249. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http:// dx. doi. org/10. 4161/onci. 25238]
250. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, et al. Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; http:// dx. doi. org/10. 4161/onci. 29179
251. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx. doi. org/ 10. 4161/onci. 28344
252. Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx. doi. org/10. 4161/ onci. 24238
253. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx. doi. org/10. 1038/nri3191
254. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2:e24612; PMID:23894720; http://dx. doi. org/10. 4161/onci. 24612
255. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70; PMID:22781695; http://dx. doi. org/10. 1038/nbt. 2287
256. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254:178-216; PMID:17383089; http://dx. doi. org/10. 1016/j. canlet. 2007. 02. 002
257. Vacchelli E, Aranda F, Eggermont A, Sautes-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014; 3: e957994; http://dx. doi. org/10. 4161/ 21624011. 2014. 957994
258. Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2:e26494; PMID:24482747; http://dx. doi. org/10. 4161/ onci. 26494
259. Morales-Kastresana A, Labiano S, Gutgemann I, Melero I. Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer. Oncoimmunology 2014; 3:e27812; PMID:25061546; http://dx. doi. org/10. 4161/ onci. 27812
260. Seo BR, Min KJ, Cho IJ, Kim SC, Kwon TK. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PLoS One 2014; 9:e95588; PMID:24743574; http://dx. doi. org/10. 1371/journal. pone. 0095588
261. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx. doi. org/ 10. 4161/onci. 1. 1. 17938
262. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; http://dx. doi. org/10. 1126/ science. 342. 6165. 1432
263. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; in press; PMID:25537519
264. Peng W, Lizee G, Hwu P. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology 2013; 2:e22691; PMID:23524510; http://dx. doi. org/10. 4161/ onci. 22691
265. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75-83; PMID:22858559; http://dx. doi. org/ 10. 1093/annonc/mds213
266. Mavilio D, Lugli E. Inhibiting the inhibitors: checkpoints blockade in solid tumors. Oncoimmunology 2013; 2:e26535; PMID:24244910; http://dx. doi. org/ 10. 4161/onci. 26535
267. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19:462-8; PMID:23169436; http://dx. doi. org/10. 1158/1078-0432. CCR-12-2625
268. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx. doi. org/10. 1056/NEJMoa1305133
269. Cooper ZA, Frederick DT, Ahmed Z, Wargo JA. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology 2013; 2:e24320; PMID:23762807; http://dx. doi. org/10. 4161/onci. 24320
270. Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology 2013; 2:e25396; PMID:23894726; http:// dx. doi. org/10. 4161/onci. 25396
271. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2:632-42; PMID:24838938; http://dx. doi. org/10. 1158/2326-6066. CIR-14-0053
272. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx. doi. org/10. 4161/ onci. 27048
273. John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2013; 2:e26286; PMID:24353912; http://dx. doi. org/10. 4161/ onci. 26286
274. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013; 19:5636-46; PMID:23873688; http://dx. doi. org/ 10. 1158/1078-0432. CCR-13-0458
275. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012; 72:5209-18; PMID:22915761; http://dx. doi. org/10. 1158/0008-5472. CAN-12-1187
276. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501-8; PMID:22326924; http://dx. doi. org/10. 1016/S1470-2045(12)70006-2
277. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx. doi. org/10. 1016/j. immuni. 2013. 07. 004
278. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011; 34:409-18; PMID:21577144; http://dx. doi. org/10. 1097/CJI. 0b013e31821ca6ce
279. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19:1008-16; PMID:21505424; http://dx. doi. org/10. 1038/ mt. 2011. 65
280. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014; 6:226ra32; PMID:24598590; http://dx. doi. org/ 10. 1126/scitranslmed. 3008095
281. Nagato T, Celis E. A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/ PD-L1 pathway. Oncoimmunology 2014; 3:e28440; PMID:25050210; http://dx. doi. org/10. 4161/ onci. 28440
282. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-17; PMID:22326922; http://dx. doi. org/10. 1016/S1470-2045(12)70007-4
283. Linch SN, Redmond WL. Combined OX40 ligation plus CTLA-4 blockade: more than the sum of its parts. Oncoimmunology 2014; 3:e28245; PMID:25050194 [http://dx. doi. org/10. 4161/ onci. 28245
284. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1:92-8; PMID:24777500; http://dx. doi. org/10. 1158/2326-6066. CIR-13-0082
285. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2:899-906; PMID:24403263; http://dx. doi. org/10. 1002/ cam4. 140
286. Hiniker SM, Chen DS, Knox SJ. Abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:2035; author reply-6; PMID:22621637; http:// dx. doi. org/10. 1056/NEJMc1203984
287. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx. doi. org/10. 1056/NEJMoa1112824
288. Demaria S, Pilones KA, Formenti SC, Dustin ML. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2013; 2:e23127; PMID:23802063; http://dx. doi. org/10. 4161/onci. 23127
289. Semeraro M, Galluzzi L. Novel insights into the mechanism of action of lenalidomide. Oncoimmunology 2014; 3:e28386; PMID:25340011; http://dx. doi. org/10. 4161/onci. 28386
290. Amin A, Ernstoff MS, Infante JR, Heng DYC, Rini BI, Plimack ER, McDermott DF, Kollmannsberger CK, Reaume MN, Spratlin JL, et al. A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2013; 31:TPS4593
291. Eggermont AM, Robert C. Melanoma: smart therapeutic strategies in immuno-oncology. Nat Rev Clin Oncol 2014; 11:181-2; PMID:24590131; http://dx. doi. org/10. 1038/nrclinonc. 2014. 36
292. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365:1747-8; PMID:22047582; http://dx. doi. org/ 10. 1056/NEJMc1110923
293. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361:211-2; PMID:19587352; http://dx. doi. org/10. 1056/NEJMc0904283
294. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2013; 2:e26333; PMID:24251081; http://dx. doi. org/10. 4161/ onci. 26333
295. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123:2447-63; PMID:23728179; http://dx. doi. org/10. 1172/JCI64859
296. Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013; 2:e26536; PMID:24404424; http://dx. doi. org/ 10. 4161/onci. 26536
297. Zitvogel L, Galluzzi L, Viaud S, Vetizou M, Daillere R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Sci Transl Med 2015; 7:271ps1; in press; PMID:25609166
298. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx. doi. org/10. 1158/1078-0432. CCR-13-3271
299. Kakavand H, Scolyer RA, Thompson JF, Mann GJ. Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. Oncoimmunology 2013; 2:e25564; PMID:24228228 [http://dx. doi. org/ 10. 4161/onci. 25564
300. Rodolfo M, Castelli C, Rivoltini L. Immune response markers in sentinel nodes may predict melanoma progression. Oncoimmunology 2014; 3:e28498; PMID:25050216; http://dx. doi. org/10. 4161/ onci. 28498
301. Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK. Biomarkers and correlative endpoints for immunotherapy trials. Am Soc Clin Oncol Educ Book 2013; PMID:23714525
302. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014; 11:509-24; PMID:25001465; http://dx. doi. org/10. 1038/nrclinonc. 2014. 111
303. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013; 19:1009-20; PMID:23460532; http://dx. doi. org/10. 1158/1078-0432. CCR-12-2982
304. Lee AF, Sieling PA, Lee DJ. Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology 2013; 2:e22889; PMID:23525606; http:// dx. doi. org/10. 4161/onci. 22889
305. Kadota K, Nitadori JI, Adusumilli PS. Prognostic value of the immune microenvironment in lung adenocarcinoma. Oncoimmunology 2013; 2:e24036; PMID:23762792; http://dx. doi. org/10. 4161/ onci. 24036
306. Escors D, Liechtenstein T, Perez-Janices N, Schwarze J, Dufait I, Goyvaerts C, Lanna A, Arce F, Blanco-Luquin I, Kochan G, et al. Assessing T-cell responses in anticancer immunotherapy: dendritic cells or myeloid-derived suppressor cells? Oncoimmunology 2013; 2:e26148; PMID:24244902; http://dx. doi. org/ 10. 4161/onci. 26148]
307. Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology 2014; 3: e27456; PMID:24800163; http://dx. doi. org/ 10. 4161/onci. 27456
308. Malyguine A, Umansky V, Kotlan B, Aptsiauri N, Shurin MR. Conference overview: cancer immunotherapy and immunomonitoring (CITIM): moving forward. J Immunotoxicol 2012; 9:231-5; PMID:22639903; http://dx. doi. org/10. 3109/ 1547691X. 2012. 686930
309. Popadic D, Anegon I, Baeten D, Eibel H, Giese T, Marits P, Martinez-Caceres E, Mascart F, Nestle F, Pujol-Borrell R, et al. Predictive immunomonitoring-the COST ENTIRE initiative. Clin Immunol 2013; 147:23-6; PMID:23454893; http://dx. doi. org/ 10. 1016/j. clim. 2013. 01. 013